A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Other criteria

• Male or female, 13-17 years of age at screening
• Has a prior primary diagnosis of ADHD according to the DSM-5 classification evident by a medical record and confirmed with MINI using DSM-5 probes
• Is taking ADHD medication 4-7 days/week, for at least 4 weeks at Screening and at least 6 weeks at Baseline
• Has side effects identified using SDSE-RS at Screening and Baseline
• CGI-S ≥ X (blinded) at Screening and Baseline
• Must be fluent in English and communicate effectively with others
• Both subject and parent/guardian willing and able to give informed assent/consent
• Parent/guardian willing to serve as informant